OBIO moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend. In 43 of 52 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on OBIO as a result. In 75 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for OBIO just turned positive on November 11, 2026. Looking at past instances where OBIO's MACD turned positive, the stock continued to rise in 29 of 48 cases over the following month. The odds of a continued upward trend are 60%.
The 10-day moving average for OBIO crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +5.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where OBIO advanced for three days, in 165 of 216 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
OBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 127 of 181 cases where OBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 56 cases where OBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. OBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.668) is normal, around the industry mean (3.498). P/E Ratio (-6.762) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.198) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The 10-day moving average for RLAY crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on RLAY as a result. In 79 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for RLAY just turned positive on November 09, 2026. Looking at past instances where RLAY's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
RLAY moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +19.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where RLAY advanced for three days, in 237 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
RLAY broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RLAY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.580) is normal, around the industry mean (3.498). P/E Ratio (-11.923) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. RLAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
OBIO | RLAY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 67 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 97 | |
PRICE GROWTH RATING 1..100 | 39 | 35 | |
P/E GROWTH RATING 1..100 | 91 | 41 | |
SEASONALITY SCORE 1..100 | 36 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RLAY's Valuation (24) in the null industry is somewhat better than the same rating for OBIO (81). This means that RLAY’s stock grew somewhat faster than OBIO’s over the last 12 months.
RLAY's Profit vs Risk Rating (100) in the null industry is in the same range as OBIO (100). This means that RLAY’s stock grew similarly to OBIO’s over the last 12 months.
RLAY's SMR Rating (97) in the null industry is in the same range as OBIO (100). This means that RLAY’s stock grew similarly to OBIO’s over the last 12 months.
RLAY's Price Growth Rating (35) in the null industry is in the same range as OBIO (39). This means that RLAY’s stock grew similarly to OBIO’s over the last 12 months.
RLAY's P/E Growth Rating (41) in the null industry is somewhat better than the same rating for OBIO (91). This means that RLAY’s stock grew somewhat faster than OBIO’s over the last 12 months.
| OBIO | RLAY | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 78% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 62% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 62% | 1 day ago 84% |
| Advances ODDS (%) | 1 day ago 76% | 3 days ago 86% |
| Declines ODDS (%) | 9 days ago 80% | 1 day ago 87% |
| BollingerBands ODDS (%) | 6 days ago 72% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 70% | 1 day ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OBIO’s FA Score shows that 0 FA rating(s) are green while RLAY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OBIO’s TA Score shows that 7 TA indicator(s) are bullish while RLAY’s TA Score has 5 bullish TA indicator(s).
OBIO (@Biotechnology) experienced а +0.17% price change this week, while RLAY (@Biotechnology) price change was +9.37% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
OBIO is expected to report earnings on Mar 31, 2027.
RLAY is expected to report earnings on Feb 25, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, OBIO has been loosely correlated with UNCY. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if OBIO jumps, then UNCY could also see price increases.
| Ticker / NAME | Correlation To OBIO | 1D Price Change % | ||
|---|---|---|---|---|
| OBIO | 100% | +4.89% | ||
| UNCY - OBIO | 35% Loosely correlated | +3.28% | ||
| RXRX - OBIO | 35% Loosely correlated | +1.13% | ||
| DMAC - OBIO | 34% Loosely correlated | -0.10% | ||
| MGX - OBIO | 33% Loosely correlated | +8.04% | ||
| RLAY - OBIO | 33% Loosely correlated | -1.10% | ||
More | ||||
A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with CGEM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then CGEM could also see price increases.
| Ticker / NAME | Correlation To RLAY | 1D Price Change % | ||
|---|---|---|---|---|
| RLAY | 100% | -1.10% | ||
| CGEM - RLAY | 46% Loosely correlated | +1.07% | ||
| LXEO - RLAY | 45% Loosely correlated | +0.33% | ||
| VIR - RLAY | 44% Loosely correlated | -0.15% | ||
| IMVT - RLAY | 44% Loosely correlated | +3.72% | ||
| VCYT - RLAY | 44% Loosely correlated | +4.36% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RBLY | 9.21 | 0.18 | +2.02% |
| Yieldmax Rblx Option Income Strategy ETF | |||
| KEAT | 32.57 | N/A | N/A |
| Keating Active ETF (KEAT) | |||
| PAWZ | 55.59 | -0.03 | -0.06% |
| ProShares Pet Care ETF (PAWZ) | |||
| FXY | 57.29 | -0.43 | -0.74% |
| Invesco Currencyshares Japanese Yen Trust (FXY) | |||
| RING | 74.52 | -1.26 | -1.66% |
| iShares MSCI Global Gold Miners ETF (RING) | |||